Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Dendreon Adds Ammo to Provenge Defense


Some analysts believe the company's stock is depressed on Medicare, sales worries.

When a drug maker charges $93,000 to treat one patient, it's going to have some haters.

New analysis suggests that Dendreon's (DNDN) prostate cancer vaccine Provenge may extend life as much as 10 months longer than patients who aren't given the treatment. That's longer than the previously reported median four months of survival benefit shown in company studies.

Since the drug was approved last year, the analysis does little more than add to the debate over cost and benefit of breakthrough treatments. Bulls continue to like Provenge and say Dendreon's stock is undervalued. Meanwhile, that sticker price is going to continue to raise eyebrows.

Despite company research showing that the treatment extends life, the big price tag stirred much discussion last year over how much we spend as a society on life-extending drugs.

"I'd like to think cost doesn't need to come up when it's a slam dunk," H. Gilbert Welch of the Dartmouth Institute for Health Policy and Clinical Practice told the Washington Post last November. "But when it's a close call like this, it certainly has to be a factor."

The folks who decide what medicines Medicare reimburses are reviewing Provenge, a factor that's depressing Dendreon's stock (see Dendreon's Provenge Overhang.) The officials aren't allowed to make a decision based on price. They say they're merely analyzing the benefit of the treatment. In November, a panel of experts advising the bureaucrats on reimbursement recommended the vaccine be covered by the government health plan (see Dendreon Passes Medicare Test.)

Dendreon traded above $55 a share after Provenge was approved for sale in the US last spring but the Medicare review scared off some investors. The stock was little changed at $34 in midday trading Friday. Some analysts predict the shares will rise again to the mid-$50s range or even higher.

The high price of Provenge, the fear that Medicare won't pay for the product, and concerns about manufacturing enough supply are all holding the shares back. Expect the stock to move up dramatically once there's clarity on the government reimbursement and production. A draft decision by the Medicare officials is expected by next month. Provenge is estimated to exceed $1 billion in annual sales.

"The company has continued to hit on most all metrics and delivering on execution of sales in 2011 and toward the goal of blockbuster status into 2012 should push the stock higher this year," RBC Capital Markets analyst Michael Yee says in a note today.

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos